Author's response to reviews

Title: monitoring the efficacy and safety of three artemisinin combinations therapies (ACT) in Senegal: results from two years surveillance

Authors:

khadime SYLLA (khadimesylla@yahoo.fr)
Annie Abiola (annie_abiola@yahoo.fr)
Roger Clement Kouly Tine (rogertine@hotmail.com)
Babacar Faye (bfaye67@yahoo.fr)
Doudou Sow (doudsow@yahoo.fr)
Jean Louis Ndiaye (jlniaye@yahoo.com)
Magatte Ndiaye (magou22000@yahoo.fr)
Amy Cole Lo (amlosn@yahoo.fr)
Oumar Gaye (ogaye@refer.sn)

Version: 2 Date: 25 May 2013

Author's response to reviews: see over
Dear Editor

One behalf of my coauthors, I make the changes requested by the editorial team of BMC infectious diseases on the manuscript entitled “monitoring the efficacy and safety of three artemisinin combinations therapies (ACT) in Senegal: results from two years surveillance” to be considered for publication in *Malaria Journal*.

I made all the necessary changes to the english, the registration number and informed consent

The study was conducted by the department of Parasitology-Mycology of the faculty of Medicine of University of Dakar which is responsible for the monitoring of the artemisinin combination therapy for malaria *Plasmodium falciparum* treatment in Senegal.

The main aim of this study was to monitor the efficacy and the safety of three artemisinin combination therapy in Senegal after several years of large use and after the recent emergence *Pf* susceptibility reduction on ACT in Asia. Our results clearly show that dihydro-artemisinine-piperaquine DHAPQ (Duocotexcin*), artemether-lumefantrine AL (Coartem*) and artesunate-amodiaquine ASAQ are effectious and well tolerated for malaria treatment in Senegal mainly in West Africa.

There is no conflict of interest in connection with this paper and the material has not been published and will not be submitted for publication elsewhere so long as it is under consideration by the *Malaria journal*. While believing that this paper may be of interest for the general reader of the *Malaria Journal*, we remain at your disposal for any further information.

Dr Khadime SYLLA